Cipher Pharmaceuticals’ preliminary results from the 02.05 Phase III study of CIP-Tramadol ER, an extended-release capsule formulation of the pain medication tramadol, did not achieve a statistically significant effect relative to placebo. While all three active treatment groups in the study demonstrated a reduction in pain from baseline, the 02.05 efficacy results did not achieve statistical significance with respect to the primary endpoint. A higher than anticipated placebo effect was ob...